LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
64.20
-0.95 (-1.46%)
At close: Apr 24, 2026, 4:00 PM EDT
64.18
-0.02 (-0.03%)
After-hours: Apr 24, 2026, 5:33 PM EDT
LivaNova Employees
LivaNova had 3,300 employees as of December 31, 2025. The number of employees increased by 400 or 13.79% compared to the previous year.
Employees
3,300
Change (1Y)
400
Growth (1Y)
13.79%
Revenue / Employee
$420,622
Profits / Employee
-$73,476
Market Cap
3.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,300 | 400 | 13.79% |
| Dec 31, 2024 | 2,900 | 0 | - |
| Dec 31, 2023 | 2,900 | 0 | - |
| Dec 31, 2022 | 2,900 | -100 | -3.33% |
| Dec 31, 2021 | 3,000 | -1,000 | -25.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bruker | 11,085 |
| Integer Holdings | 11,000 |
| AdaptHealth | 10,900 |
| Haemonetics | 3,023 |
| Neogen | 2,974 |
| iRhythm Holdings | 2,400 |
| Artivion | 1,800 |
| Glaukos | 1,094 |
LIVN News
- 5 days ago - Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea - Business Wire
- 4 weeks ago - LivaNova to Announce First-Quarter 2026 Results - Business Wire
- 5 weeks ago - LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea - Business Wire
- 2 months ago - LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance - Business Wire
- 3 months ago - LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results - Business Wire
- 4 months ago - LivaNova to Present at J.P. Morgan Healthcare Conference in January - Business Wire
- 5 months ago - LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting - Business Wire
- 5 months ago - LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea - Business Wire